Literature DB >> 35792761

Liver cirrhosis and immune dysfunction.

Elda Hasa1, Phillipp Hartmann1,2,3, Bernd Schnabl1,4.   

Abstract

Cirrhosis is end-stage liver disease resulting from various etiologies and is a common cause of death worldwide. The progression from compensated to decompensated cirrhosis to acute-on-chronic liver failure (ACLF) is due to multiple factors, including continuation of alcohol use or continued exposure to other toxins, an imbalance of the gut microbiota (dysbiosis), increased gut permeability and a disrupted immune response. This disrupted immune response is also named cirrhosis-associated immune dysfunction, which is characterized by worsening systemic inflammation with concomitant immune paralysis, as liver disease deteriorates. This review highlights central immunologic events during the exacerbation of cirrhosis and characterizes the different immune cell populations involved therein. Published by Oxford University Press on behalf of The Japanese Society for Immunology 2022.

Entities:  

Keywords:  acute-on-chronic liver failure (ACLF); cirrhosis-associated immune dysfunction (CAID); compensated and decompensated cirrhosis; immune paralysis; inflammation

Mesh:

Year:  2022        PMID: 35792761      PMCID: PMC9447994          DOI: 10.1093/intimm/dxac030

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   5.071


  183 in total

1.  Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.

Authors:  Katharina Brandl; Phillipp Hartmann; Lily J Jih; Donald P Pizzo; Josepmaria Argemi; Meritxell Ventura-Cots; Sally Coulter; Christopher Liddle; Lei Ling; Stephen J Rossi; Alex M DePaoli; Rohit Loomba; Wajahat Z Mehal; Derrick E Fouts; Michael R Lucey; Francisco Bosques-Padilla; Philippe Mathurin; Alexander Louvet; Guadalupe Garcia-Tsao; Elizabeth C Verna; Juan G Abraldes; Robert S Brown; Victor Vargas; Jose Altamirano; Juan Caballería; Debbie Shawcross; Peter Stärkel; Samuel B Ho; Ramon Bataller; Bernd Schnabl
Journal:  J Hepatol       Date:  2018-04-12       Impact factor: 25.083

2.  Risk factors for progression of and treatment options for NAFLD in children.

Authors:  Phillipp Hartmann; Bernd Schnabl
Journal:  Clin Liver Dis (Hoboken)       Date:  2018-01-31

3.  Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis.

Authors:  Beate Appenrodt; Frank Grünhage; Martin G Gentemann; Lydia Thyssen; Tilman Sauerbruch; Frank Lammert
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

4.  Bactericidal and opsonic activity of ascitic fluid from cirrhotic and noncirrhotic patients.

Authors:  H E Akalin; Y Laleli; H Telatar
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

5.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

6.  Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice.

Authors:  Phillipp Hartmann; Peng Chen; Hui J Wang; Lirui Wang; Declan F McCole; Katharina Brandl; Peter Stärkel; Clara Belzer; Claus Hellerbrand; Hidekazu Tsukamoto; Samuel B Ho; Bernd Schnabl
Journal:  Hepatology       Date:  2013-05-27       Impact factor: 17.425

Review 7.  Fluid retention in cirrhosis: pathophysiology and management.

Authors:  A Kashani; C Landaverde; V Medici; L Rossaro
Journal:  QJM       Date:  2008-01-09

8.  Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients.

Authors:  Ming Shi; Zheng Zhang; Ruonan Xu; Hu Lin; Junliang Fu; Zhengsheng Zou; Aimin Zhang; Jianfei Shi; Liming Chen; Sa Lv; Weiping He; Hua Geng; Lei Jin; Zhenwen Liu; Fu-Sheng Wang
Journal:  Stem Cells Transl Med       Date:  2012-10-11       Impact factor: 6.940

9.  Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes.

Authors:  Sebastian Seidler; Henning W Zimmermann; Ralf Weiskirchen; Christian Trautwein; Frank Tacke
Journal:  BMC Gastroenterol       Date:  2012-04-24       Impact factor: 3.067

10.  A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.

Authors:  Frederik Nevens; Thierry Gustot; Pierre-François Laterre; Luc L Lasser; Lyudmil E Haralampiev; Victor Vargas; Desislava Lyubomirova; Agustin Albillos; Mustapha Najimi; Sébastien Michel; Ivaylo Stoykov; Noelia Gordillo; Yelena Vainilovich; Virginie Barthel; Nathalie Clerget-Chossat; Etienne M Sokal
Journal:  JHEP Rep       Date:  2021-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.